Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Matthias P Wymann Clear advanced filters

  • Causally linking a mutation to clinical phenotypes in rare hereditary diseases is both challenging and illuminating. Here the authors identify PI3Kɣ mutations in a patient with immune dysregulation, and recapitulate the phenotypes in PI3Kɣ-deficient mice by exposing them to natural microbiota from pet-shop mice.

    • Andrew J. Takeda
    • Timothy J. Maher
    • Carrie L. Lucas
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-12

  • When combined, two drugs alter the activity of a protein complex called target of rapamycin complex 1 such that it is inhibited in the brain but not the body, enabling the treatment of brain tumours in mice without systemic toxicity.

    • Matthias P. Wymann
    • Chiara Borsari
    News & Views
    Nature
    Volume: 609, P: 681-683

  • The activation and infiltration of immune cells to the vasculature is intimately linked to the immunopathology of hypertension. Here the authors implicate PI3Kγ signalling in the trafficking of CD8+ T cells between lymphoid and non-lymphoid organs, and the development of hypertension in a murine model.

    • Marialuisa Perrotta
    • Sara Perrotta
    • Daniela Carnevale
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-19

  • Buparlisib/BKM120 is in phase 3 clinical trials as a phosphoinositide 3-kinase (PI3K) inhibitor. Here, Bohnackeret al. combine chemical biology and structural biology approaches to segregate BKM120’s biological actions, and suggest that it causes mitotic arrest predominantly by binding microtubules and disrupting their dynamics.

    • Thomas Bohnacker
    • Andrea E. Prota
    • Matthias P. Wymann
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-13

  • Lipids function as extracellular and intracellular messengers in a complex lipid signalling network that controls important cellular processes. Imbalances in this network contribute to the pathogenesis of different diseases, including cancer, inflammation and metabolic syndrome, which therefore share common points of therapeutic intervention.

    • Matthias P. Wymann
    • Roger Schneiter
    Reviews
    Nature Reviews Molecular Cell Biology
    Volume: 9, P: 162-176

  • Combining X-ray structures, surface plasmon resonance and hydrogen-deuterium exchange–mass spectrometry, a class of highly selective inhibitors was found to bind to an active state of PI3Kγ breaking a conformational ‘lock’ important for activation of PI3Kγ.

    • Gangadhara Gangadhara
    • Göran Dahl
    • Jens Petersen
    Research
    Nature Chemical Biology
    Volume: 15, P: 348-357

  • This Review discusses the immunomodulatory properties of phosphoinositide 3-kinase-γ (PI3Kγ) in health and in the context of various diseases, ranging from cardiovascular disease to auto-immunity and cancer, and discusses the therapeutic potential of PI3Kγ inhibitors, which have entered clinical trials for cancer.

    • Stephen M. Lanahan
    • Matthias P. Wymann
    • Carrie L. Lucas
    Reviews
    Nature Reviews Immunology
    Volume: 22, P: 687-700

  • Phosphatidylinositol 3-kinase (PI3K)γ is an emerging target for the development of drugs with anti-inflammatory and/or cardioprotective activity. Rommel and colleagues review the biology of this key signalling molecule and discuss current efforts to develop selective PI3Kγ inhibitors.

    • Thomas Rückle
    • Matthias K. Schwarz
    • Christian Rommel
    Reviews
    Nature Reviews Drug Discovery
    Volume: 5, P: 903-918